besilesomab
glembatumumab
atezolizumab
cemiplimab
sibrotuzumab
pidilizumab
ravulizumab
brolucizumab
gevokizumab
olaratumab
abagovomab
etaracizumab
fontolizumab
amlitelimab
tislelizumab
zalutumumab
inotuzumab ozogamicin
bivatuzumab
-lim-
ozogamicin
olendalizumab
lexatumumab
intrabody
antimonoclonal
-toxa-
ipilimumab
tigatuzumab
rapid antigen test
agonistic monoclonal antibody
tabalumab
dalotuzumab
-zumab
immunochemiluminometric
Forssman antibody
durvalumab
brodalumab
heterophil antibody
microlymphocytotoxicity
heterophile antibody
talacotuzumab
immunofluorescence
lenzilumab
immunostrip
immunolabeling
bectumomab
ocrelizumab
-o-
antinucleosome
siltuximab
robatumumab